Correction to: Programmed death 1 ligand (PD-L1) in solid cancers after allogeneic hematopoietic stem cell transplantation: a retrospective analysis by the Nagasaki Transplant Group

[1]  K. Akashi,et al.  Combination of CD47 and signal‐regulatory protein‐α constituting the “don’t eat me signal” is a prognostic factor in diffuse large B‐cell lymphoma , 2020, Cancer science.

[2]  E. Sturgis,et al.  Human Papillomavirus Testing in Head and Neck Carcinomas: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists Guideline. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  A. Sharpe,et al.  PD-L1 Prevents the Development of Autoimmune Heart Disease in Graft-versus-Host Disease , 2018, The Journal of Immunology.

[4]  B. Akgül,et al.  Molecular Mechanisms of Human Papillomavirus Induced Skin Carcinogenesis , 2017, Viruses.

[5]  K. Harrington,et al.  Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. , 2016, The New England journal of medicine.

[6]  M. Seto,et al.  PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia/lymphoma. , 2016, Blood.

[7]  W. Cooper,et al.  The Role of Tumor‐Infiltrating Lymphocytes in Development, Progression, and Prognosis of Non–Small Cell Lung Cancer , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[8]  Satoru Miyano,et al.  Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers , 2016, Nature.

[9]  K. Ohshima,et al.  Prognostic Value of Programmed Death Ligand 1 and Programmed Death 1 Expression in Thymic Carcinoma , 2016, Clinical Cancer Research.

[10]  L. Ashton,et al.  Second Cancer Risk and Late Mortality in Adult Australians Receiving Allogeneic Hematopoietic Stem Cell Transplantation: A Population-Based Cohort Study. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[11]  A. Ravaud,et al.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.

[12]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[13]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[14]  D. Powell,et al.  Tumor infiltrating lymphocytes in ovarian cancer , 2015, Cancer biology & therapy.

[15]  P. Howley,et al.  Beta genus papillomaviruses and skin cancer. , 2015, Virology.

[16]  C. Drake,et al.  Immune checkpoint blockade: a common denominator approach to cancer therapy. , 2015, Cancer cell.

[17]  T. Nielsen,et al.  The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  M. Millenson,et al.  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. , 2015, The New England journal of medicine.

[19]  K. Kawa,et al.  Continuing increased risk of oral/esophageal cancer after allogeneic hematopoietic stem cell transplantation in adults in association with chronic graft-versus-host disease. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  J. Wolchok,et al.  Immune modulation in cancer with antibodies. , 2014, Annual review of medicine.

[21]  G. Freeman,et al.  Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality. , 2013, Blood.

[22]  Stephanie J. Lee,et al.  Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  J. Taube,et al.  Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. , 2013, Cancer research.

[24]  H. Nakasone,et al.  Late Mortality and Causes of Death among Long-Term Survivors after Allogeneic Stem Cell Transplantation. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[25]  Y. Kanda,et al.  Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.

[26]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[27]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[28]  Alison P. Klein,et al.  Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape , 2012, Science Translational Medicine.

[29]  P. Gaffney,et al.  Evidence for gene-gene epistatic interactions among susceptibility loci for systemic lupus erythematosus. , 2012, Arthritis and rheumatism.

[30]  N. Majhail.  Secondary cancers following allogeneic haematopoietic cell transplantation in adults , 2011, British journal of haematology.

[31]  Michael Boeckh,et al.  Reduced mortality after allogeneic hematopoietic-cell transplantation. , 2010, The New England journal of medicine.

[32]  J. Wingard,et al.  Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning. , 2010, Blood.

[33]  Jing Xu,et al.  Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1 , 2009, The Journal of experimental medicine.

[34]  F. Xiao,et al.  Association between the PD1.3A/G polymorphism of the PDCD1 gene and systemic lupus erythematosus in European populations: a meta‐analysis , 2009, Journal of the European Academy of Dermatology and Venereology : JEADV.

[35]  B. Sandmaier,et al.  Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[36]  H. Deeg,et al.  Solid cancers after allogeneic hematopoietic cell transplantation. , 2009, Blood.

[37]  G. Freeman,et al.  PD-1 and its ligands in tolerance and immunity. , 2008, Annual review of immunology.

[38]  G. Rabinovich,et al.  Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment , 2007, Cancer Immunology, Immunotherapy.

[39]  L. Prokunina-Olsson,et al.  Association of PDCD1 genetic variation with risk and clinical manifestations of systemic lupus erythematosus in a multiethnic cohort , 2007, Genes and Immunity.

[40]  A. Mackensen,et al.  Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion , 2007, Cancer Immunology, Immunotherapy.

[41]  K. Ihara,et al.  PD-1 gene haplotype is associated with the development of type 1 diabetes mellitus in Japanese children , 2007, Human Genetics.

[42]  Edward A Copelan,et al.  Hematopoietic stem-cell transplantation. , 2006, The New England journal of medicine.

[43]  W. Asavaroengchai,et al.  Role of Interferon-gamma in GVHD and GVL. , 2005, Cellular & molecular immunology.

[44]  Y. Kodera,et al.  Solid tumors after hematopoietic stem cell transplantation in Japan: incidence, risk factors and prognosis , 2005, Bone Marrow Transplantation.

[45]  W. Travis,et al.  Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study. , 2005, Blood.

[46]  L. Prokunina-Olsson,et al.  A new haplotype of PDCD1 is associated with rheumatoid arthritis in Hong Kong Chinese. , 2005, Arthritis and rheumatism.

[47]  S. Syrjänen.  Human papillomavirus (HPV) in head and neck cancer. , 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[48]  U. de Faire,et al.  Association of the PD-1.3A allele of the PDCD1 gene in patients with rheumatoid arthritis negative for rheumatoid factor and the shared epitope. , 2004, Arthritis and rheumatism.

[49]  S. Husby,et al.  Association of a putative regulatory polymorphism in the PD-1 gene with susceptibility to type 1 diabetes. , 2003, Tissue antigens.

[50]  L. Robison,et al.  New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  R. Jonsson,et al.  A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans , 2002, Nature Genetics.

[52]  Yoshimasa Tanaka,et al.  Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[53]  C. Miller,et al.  Human papillomavirus as a risk factor for oral squamous cell carcinoma: a meta-analysis, 1982-1997. , 2001, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[54]  A. Nademanee,et al.  Solid cancers after bone marrow transplantation. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  T. Wheeler,et al.  Reduced infiltration of tumor-associated macrophages in human prostate cancer: association with cancer progression. , 2000, Cancer research.

[56]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[57]  J Crowley,et al.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.

[58]  R. Hoover,et al.  Solid cancers after bone marrow transplantation. , 1997, The New England journal of medicine.

[59]  E D Thomas,et al.  1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.

[60]  K. Sullivan,et al.  Chronic graft-versus-host disease and other late complications of bone marrow transplantation. , 1991, Seminars in hematology.

[61]  P. Fasching,et al.  Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. , 2018, The Lancet. Oncology.

[62]  J. Ajani,et al.  Tumor-associated macrophage infiltration is highly associated with PD-L1 expression in gastric adenocarcinoma , 2017, Gastric Cancer.

[63]  Y. Kanda,et al.  Secondary solid tumors after allogeneic hematopoietic SCT in Japan , 2012, Bone Marrow Transplantation.